carboplatin + etoposide + nivolumab

This is a **three-drug combination therapy** composed of carboplatin, etoposide, and nivolumab, primarily studied as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) and evaluated for other high-grade neuroendocrine neoplasms. Carboplatin is a platinum-based chemotherapeutic that induces DNA cross-linking and apoptosis. Etoposide is a topoisomerase II inhibitor leading to DNA strand breaks and cell death. Nivolumab is a monoclonal antibody that acts as an immune checkpoint inhibitor by blocking programmed death-1 (PD-1) receptor, thereby enhancing anti-tumor immune responses. This regimen is administered intravenously and is under clinical investigation for its ability to prolong progression-free and overall survival in settings where standard platinum-etoposide-based therapies are used, especially in combination with immunotherapy agents[1][2][3][4].